Voyager Therapeutics, Inc.
VYGR
$3.17
-$0.26-7.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 66.96M | 80.00M | 163.78M | 143.77M | 119.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.96M | 80.00M | 163.78M | 143.77M | 119.04M |
| Cost of Revenue | 129.03M | 124.59M | 117.54M | 113.16M | 100.70M |
| Gross Profit | -62.07M | -44.59M | 46.24M | 30.61M | 18.35M |
| SG&A Expenses | 36.95M | 35.92M | 37.17M | 37.26M | 35.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 165.98M | 160.51M | 154.71M | 150.42M | 136.10M |
| Operating Income | -99.02M | -80.51M | 9.08M | -6.65M | -17.05M |
| Income Before Tax | -84.01M | -64.34M | 26.78M | 9.71M | -2.33M |
| Income Tax Expenses | 688.00K | 665.00K | 903.00K | 683.00K | 718.00K |
| Earnings from Continuing Operations | -84.69 | -65.00 | 25.88 | 9.02 | -3.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.69M | -65.00M | 25.88M | 9.02M | -3.04M |
| EBIT | -99.02M | -80.51M | 9.08M | -6.65M | -17.05M |
| EBITDA | -94.47M | -75.78M | 14.13M | -1.78M | -12.49M |
| EPS Basic | -1.46 | -1.13 | 0.75 | 0.32 | -0.02 |
| Normalized Basic EPS | -0.87 | -0.67 | 0.48 | 0.21 | 0.00 |
| EPS Diluted | -1.47 | -1.14 | 0.71 | 0.28 | -0.05 |
| Normalized Diluted EPS | -0.87 | -0.67 | 0.46 | 0.19 | -0.02 |
| Average Basic Shares Outstanding | 231.90M | 230.66M | 216.67M | 202.69M | 188.49M |
| Average Diluted Shares Outstanding | 231.90M | 230.66M | 217.77M | 203.78M | 189.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |